Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Expanded Access to Upadacitinib

NCT04159597 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT04159597
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04159597 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Expanded Access to Upadacitinib
Lead sponsor
AbbVie
Phase
Expanded access
Overall status
Available
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

alopecia areata, atopic dermatitis, axial spondyloarthritis, crohn disease, giant cell arteritis, hidradenitis suppurativa, idiopathic arthritis (including sjia, pjia, or jpsa), non segmental vitiligo, non-radiographic axial, psoriatic arthritis, rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, ulcerative colitis